New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.09x net interest cover). Minor Risks Negative equity (-US$18m). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$30.9m market cap). Ankündigung • May 09
Cryo-Cell International, Inc. Receives Acceptance of Compliance Plan from NYSE American On May 6, 2026, Cryo-Cell International, Inc. (the "Company") received a written notice from NYSE Regulation stating that it had accepted the Company's plan to regain compliance with the continued listing standards of the NYSE American LLC ("NYSE American"). As previously disclosed, the Company submitted a compliance plan to NYSE American on April 8, 2026. NYSE Regulation accepted the plan and granted the Company a plan period through September 9, 2027 to regain compliance with the applicable continued listing standards. During the plan period, the Company's common stock will continue to be listed and traded on NYSE American, subject to the Company's compliance with the initiatives and conditions set forth in the compliance plan and continued periodic review by NYSE Regulation. There can be no assurance that the Company will be able to regain compliance with the NYSE American continued listing standards by the September 9, 2027 plan period deadline. If the Company fails to regain compliance by such date, or fails to make progress consistent with the accepted compliance plan during the plan period, NYSE American may initiate delisting proceedings. Reported Earnings • Apr 16
First quarter 2026 earnings: EPS exceeds analyst expectations First quarter 2026 results: EPS: US$0.006 (down from US$0.035 in 1Q 2025). Revenue: US$7.68m (down 3.6% from 1Q 2025). Net income: US$47.1k (down 83% from 1Q 2025). Profit margin: 0.6% (down from 3.5% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is expected to decline by 5.5% p.a. on average during the next 2 years, while revenues in the Healthcare industry in the US are expected to grow by 4.8%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Ankündigung • Mar 13
Cryo-Cell International, Inc. Receives NYSE American Continued Listing Notice Cryo-Cell International, Inc. announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30, 2023, November 30, 2024 and November 30, 2025. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American requirements, the Company intends to submit a plan to regain compliance within the prescribed timeframe. If the plan is accepted, the Company is typically granted a period of up to 18 months from receipt of the Notice to regain compliance. During this period, the Company’s common stock will continue to be listed and traded on the NYSE American, subject to the Company’s compliance with other listing requirements and the plan accepted by the NYSE American. There can be no assurance that the Company will be able to regain compliance within the allotted time or that the NYSE American will grant the Company an extension of time to regain compliance. If the Company fails to regain compliance or fails to maintain compliance with other listing requirements, the NYSE American may initiate delisting proceedings. Reported Earnings • Mar 02
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$0.30 loss per share (down from US$0.049 profit in FY 2024). Revenue: US$31.6m (down 1.3% from FY 2024). Net loss: US$2.43m (down US$2.83m from profit in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Dec 02
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to US$3.57. The fair value is estimated to be US$4.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 4.6% in a year. Earnings are forecast to decline by 398% in the next year. Reported Earnings • Oct 16
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: US$0.093 (down from US$0.13 in 3Q 2024). Revenue: US$7.83m (down 3.0% from 3Q 2024). Net income: US$749.4k (down 29% from 3Q 2024). Profit margin: 9.6% (down from 13% in 3Q 2024). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to stay flat during the next 2 years compared to a 5.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Ankündigung • Sep 29
Cryo-Cell International, Inc., Annual General Meeting, Oct 21, 2025 Cryo-Cell International, Inc., Annual General Meeting, Oct 21, 2025. Location: 700 brooker creek blvd., suite 1800, florida 34677, oldsmar United States Recent Insider Transactions • Sep 12
Chairman & Co-CEO recently bought US$158k worth of stock On the 10th of September, David Portnoy bought around 36k shares on-market at roughly US$4.42 per share. This transaction amounted to 2.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$176k. David has been a buyer over the last 12 months, purchasing a net total of US$443k worth in shares. Recent Insider Transactions • Aug 21
Chairman & Co-CEO recently bought US$85k worth of stock On the 19th of August, David Portnoy bought around 19k shares on-market at roughly US$4.41 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. David has been a buyer over the last 12 months, purchasing a net total of US$109k worth in shares. Ankündigung • Aug 14
Cryo-Cell International, Inc. Not to Declare Dividend for Third Quarter of Fiscal 2025 Cryo-Cell International, Inc. announced that the Company will not declare a quarterly cash dividend for the third quarter of fiscal 2025. Major Estimate Revision • Jul 22
Consensus EPS estimates increase from loss to US$0.00 profit The consensus outlook for fiscal year 2025 has been updated. 2025 forecast for profit of -US$0.12 instead of a loss of US$0.00 per share previously. Revenue forecast unchanged at US$31.9m. Healthcare industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$8.50 unchanged from last update. Share price rose 7.7% to US$5.29 over the past week. Reported Earnings • Jul 16
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: US$0.044 (down from US$0.081 in 2Q 2024). Revenue: US$7.93m (down 1.4% from 2Q 2024). Net income: US$355.8k (down 46% from 2Q 2024). Profit margin: 4.5% (down from 8.2% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to stay flat during the next 2 years compared to a 6.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 14
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 21 May 2025. Payment date: 30 May 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 20%. Within top quartile of American dividend payers (4.7%). Higher than average of industry peers (2.3%). Ankündigung • May 09
Cryo-Cell International, Inc. Declares Quarterly Cash Dividend, Payable on May 30, 2025 Cryo-Cell International, Inc. announced that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company’s dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. Reported Earnings • Apr 15
First quarter 2025 earnings released: EPS: US$0.035 (vs US$0.067 in 1Q 2024) First quarter 2025 results: EPS: US$0.035 (down from US$0.067 in 1Q 2024). Revenue: US$7.97m (up 1.5% from 1Q 2024). Net income: US$282.9k (down 49% from 1Q 2024). Profit margin: 3.5% (down from 7.1% in 1Q 2024). Revenue is forecast to stay flat during the next 2 years compared to a 7.3% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. New Risk • Mar 04
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 69% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.2x net interest cover). Earnings are forecast to decline by an average of 69% per year for the foreseeable future. Minor Risks Negative equity (-US$13m). Large one-off items impacting financial results. Market cap is less than US$100m (US$54.2m market cap). Reported Earnings • Mar 02
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: US$0.049 (up from US$1.14 loss in FY 2023). Revenue: US$32.0m (up 2.0% from FY 2023). Net income: US$402.1k (up US$9.92m from FY 2023). Profit margin: 1.3% (up from net loss in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 83%. Revenue is forecast to stay flat during the next 2 years compared to a 7.1% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. New Risk • Mar 02
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risks Negative equity (-US$13m). Large one-off items impacting financial results. Market cap is less than US$100m (US$63.7m market cap). Upcoming Dividend • Feb 07
Upcoming dividend of US$0.25 per share Eligible shareholders must have bought the stock before 14 February 2025. Payment date: 28 February 2025. Trailing yield: 2.9%. Lower than top quartile of American dividend payers (4.5%). Higher than average of industry peers (1.9%). Ankündigung • Jan 30
Cryo-Cell International, Inc. Announces Regular Quarterly Cash Dividend, Payable on February 28, 2025 Cryo-Cell International, Inc. announced that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company’s dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. Recent Insider Transactions Derivative • Nov 17
Chief Information Officer exercised options to buy US$169k worth of stock. On the 12th of November, Oleg Mikulinsky exercised options to buy 20k shares at a strike price of around US$3.77, costing a total of US$75k. This transaction amounted to 24% of their direct individual holding at the time of the trade. Since December 2023, Oleg's direct individual holding has increased from 84.35k shares to 104.35k. This was the only transaction from an insider over the last 12 months. Upcoming Dividend • Nov 08
Inaugural dividend of US$0.25 per share Eligible shareholders must have bought the stock before 15 November 2024. Payment date: 29 November 2024. This is the first dividend for Cryo-Cell International since going public. The average dividend yield among industry peers is 1.6%. Ankündigung • Oct 30
Cryo-Cell International, Inc. Declares Initiation of Regular Quarterly Cash Dividend, Payable on November 29, 2024 Cryo-Cell International, Inc. announced that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company’s earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future dividend payments may be increased or decreased and there is no assurance that future dividends will be paid. Price Target Changed • Oct 20
Price target decreased by 18% to US$9.00 Down from US$11.00, the current price target is provided by 1 analyst. New target price is 42% above last closing price of US$6.34. Stock is up 40% over the past year. The company is forecast to post earnings per share of US$0.29 next year compared to a net loss per share of US$1.14 last year. Reported Earnings • Oct 16
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$0.13 (up from US$0.082 in 3Q 2023). Revenue: US$8.07m (up 2.5% from 3Q 2023). Net income: US$1.05m (up 55% from 3Q 2023). Profit margin: 13% (up from 8.6% in 3Q 2023). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Board Change • Oct 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Co-CEO & Director Mark Portnoy was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Sep 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Negative equity (-US$11m). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (US$55.0m market cap). Ankündigung • Sep 18
Cryo-Cell International, Inc., Annual General Meeting, Oct 29, 2024 Cryo-Cell International, Inc., Annual General Meeting, Oct 29, 2024. Reported Earnings • Jul 16
Second quarter 2024 earnings: EPS exceeds analyst expectations Second quarter 2024 results: EPS: US$0.081 (up from US$0.027 in 2Q 2023). Revenue: US$8.04m (up 3.5% from 2Q 2023). Net income: US$655.8k (up 197% from 2Q 2023). Profit margin: 8.2% (up from 2.8% in 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 100%. Revenue is forecast to grow 7.7% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 16
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: EPS: US$0.067 (down from US$0.091 in 1Q 2023). Revenue: US$7.85m (flat on 1Q 2023). Net income: US$556.2k (down 28% from 1Q 2023). Profit margin: 7.1% (down from 9.8% in 1Q 2023). Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 7.0% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 01
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$1.14 loss per share (down from US$0.33 profit in FY 2022). Revenue: US$31.3m (up 3.3% from FY 2022). Net loss: US$9.52m (down 444% from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance. New Risk • Dec 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Earnings are forecast to decline by an average of 86% per year for the foreseeable future. Minor Risks Negative equity (-US$16k). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$54.7m market cap). Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 36% After last week's 36% share price gain to US$5.84, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 19x in the Healthcare industry in the US. Total loss to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$4.22, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 18x in the Healthcare industry in the US. Total loss to shareholders of 37% over the past three years. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to US$5.04, the stock trades at a forward P/E ratio of 61x. Average forward P/E is 17x in the Healthcare industry in the US. Total loss to shareholders of 13% over the past three years. New Risk • Oct 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 86% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Earnings are forecast to decline by an average of 86% per year for the foreseeable future. Minor Risks Negative equity (-US$16k). Market cap is less than US$100m (US$40.8m market cap). Reported Earnings • Oct 13
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: US$0.082 (up from US$0.056 in 3Q 2022). Revenue: US$7.87m (up 2.5% from 3Q 2022). Net income: US$680.6k (up 46% from 3Q 2022). Profit margin: 8.6% (up from 6.1% in 3Q 2022). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Ankündigung • Sep 15
Cryo-Cell International, Inc., Annual General Meeting, Oct 10, 2023 Cryo-Cell International, Inc., Annual General Meeting, Oct 10, 2023, at 11:00 US Eastern Standard Time. Location: 700 Brooker Creek Blvd., Suite 1800, Oldsmar, Florida 34677 Oldsmar Florida United States Agenda: To consider for election four individuals named in the attached proxy statement to the Company's Board of Directors; to ratify the appointment of Wipfli LLP as our independent registered public accountants for the fiscal year ending November 30, 2023; to consider and approve a non-binding advisory resolution regarding the compensation of the Company's named executive officers; and to consider and take action upon such other matters as may properly be brought before the meeting or any postponements or adjournments thereof by or at the direction of the Board of Directors. Price Target Changed • Aug 31
Price target decreased by 17% to US$10.00 Down from US$12.00, the current price target is provided by 1 analyst. New target price is 67% above last closing price of US$6.00. Stock is down 14% over the past year. The company is forecast to post earnings per share of US$0.01 for next year compared to US$0.33 last year. Ankündigung • Sep 01
Cryo-Cell International Common Stock Deleted from Other OTC Cryo-Cell International, Inc. Common Stock has been deleted from other OTC effective from August 31, 2021, due to Market Center Change Listed on NASDAQ. Ankündigung • Feb 27
Cryo-Cell International Enters into an Exclusive License Agreement with Duke University Cryo-Cell International, Inc. has entered into a collaborative license agreement with Duke University. The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke. Cryo-Cell plans to explore, test, and administer these treatments to patients with conditions for which there are limited FDA approved therapies, including cerebral palsy, autism, multiple sclerosis and COVID-19. These treatments utilize the unique immunomodulatory and potential regenerative properties derived from cord blood and cord tissue. Under the agreement, Cryo-Cell has been granted exclusive commercial rights to Duke’s intellectual property assets, FDA regulatory data, clinical expertise and manufacturing protocols associated with various applications of cord blood and cord tissue stem cells. Through this agreement, Cryo-Cell intends to expand to a triad of core business units: its renowned cord blood bank, biopharmaceutical manufacturing (once BLA(s) or Emergency Use Authorization(s) are approved by the FDA), and infusion clinic(s) services, initially under the rights granted to Duke through the FDA’s Expanded Access Program. As a result of this partnership with Duke University, Cryo-Cell’s Board of Directors is actively considering uplisting the Company’s common stock to a NASDAQ listing.